Osteoporosis and fractures associated with drugs;Osteoporose og frakturer, der er associeret med lægemidler Oversigtsartikel

Ugeskrift for Laeger

Volumn 170, Issue 18, 2008, Pages 1550-1555

  Vestergaard, Peter ^a   Rejnmark, Lars ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DRUG;

BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; OSTEOPOROSIS; PATHOLOGIC FRACTURE; REVIEW; RISK FACTOR;

ANALGESICS; ANTINEOPLASTIC AGENTS; BONE DENSITY; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; FRACTURES, SPONTANEOUS; HUMANS; HYPOGLYCEMIC AGENTS; OSTEOPOROSIS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 44349112840     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of anti-epileptic drugs. Epilepsia 2004;45:1330-7.
2. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporosis Int 2006;17:807-16.
3. Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of Lithium. Calcif Tissue Int 2005;77:1-8.
4. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292-9.
5. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
6. Rejnmark L, Vestergaard P, Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 2005;76:167-75.
7. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with loop diuretics. J Int Med 2006;259:117-24.
8. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006;24:581-9.
9. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos Int 2006;18:409-17.
10. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 2007;118;338-44.
11. Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 2006;21:1811-7.
12. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83.
13. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of morphine and opiates. J Intern Med 2006;260:76-87.
14. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int 2006;79:84-94.
15. Vestergaard P, Rejnmark L, Mosekilde L. Methotrexate, azathioprine, cyclosporine, and risk of fracture. Calcif Tissue Int 2006;79:69-75.
16. Mincey BA, Duh MS, Thomas SK et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006;7:127-32.
17. Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand 2005;112:277-86.
18. Gissel T, Poulsen CS, Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf 2007;6:267-78.
19. Vestergaard P, Emborg C, Støving RK et al. Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders - a nation-wide register study. Int J Eat Disord 2002;32:301-8.
20. Higuchi T, Komoda T, Sugishita M et al. Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiology 1987;18:185-8.
21. Bliziotes M, Gunness M, Eshleman A et al. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact 2002;2:291-5.
22. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007;18:427-44.
23. Vestergaard P. Osteoporosis and fracture risk in patients with diabetes. SIIC 2006;11:1.
24. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54.
25. Ali AA, Weinstein RS, Stewart SA et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-35.
26. Rejnmark L, Vestergaard P, Pedersen AR et al. Dose-effect relations of loop- and thiazide diuretics on calcium homeostasis: a randomized, double blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest 2003;33:41-50.
27. Jones G, Nguyen T, Sambrook PN et al. Thiazide diuretics and fractures: can meta-analysis help? J.Bone Miner Res 1995;10:106-11.
28. LaCroix AZ, Ott SM, Ichikawa L et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. Ann Intern Med 2000;133:516-26.
29. Reid IR, Ames RW, Orr-Walker BJ et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women. Am J Med 2000;109:362-70.
30. Rejnmark L, Vestergaard P, Heickendorff L et al. Loop diuretics alter the diurnal rhytm of endogenous parathyroid hormone secretion. Eur J Clin Invest 2001;31:764-72.
31. Rejnmark L, Vestergaard P, Heickendorff L et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women. J Bone Miner Res 2006;21:163-70.
32. Rejnmark L, Vestergaard P, Mosekilde L. Statin but not non-statin lipid-lowering drugs decrease fracture risk. Calcif Tissue Int 2006;79:27-36.
33. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9.
34. Oxlund H, Andreassen TT. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 2004;34:609-18.
35. Rejnmark L, Buus NH, Vestergaard P et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004;19:737-44.
36. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002;8:276-9.
37. Caraballo PJ, Gabriel SE, Castro MR et al. Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporosis Int 1999;9:441-8.
38. Jamal SA, Browner WS, Bauer DC, et al. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann.Intern.Med. 1998;128:829-32.
39. Lovell SJ, Taira T, Rodriguez E et al. Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department. Acad Emerg Med 2004;11:1278-82.
40. Love RR, Maxess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.